These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15129430)
1. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells. Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716 [TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
4. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo. Palmer J; Ernst M; Hammacher A; Hertzog PJ Prostate; 2005 Feb; 62(3):282-9. PubMed ID: 15389784 [TBL] [Abstract][Full Text] [Related]
5. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616 [TBL] [Abstract][Full Text] [Related]
7. PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Lu S; Ren C; Liu Y; Epner DE Int J Oncol; 2006 Jan; 28(1):245-51. PubMed ID: 16328002 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Lee SO; Lou W; Johnson CS; Trump DL; Gao AC Prostate; 2004 Aug; 60(3):178-86. PubMed ID: 15176047 [TBL] [Abstract][Full Text] [Related]
9. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells. Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330 [TBL] [Abstract][Full Text] [Related]
12. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression. Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613 [TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Xie Y; Wolff DW; Lin MF; Tu Y Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995 [TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165 [TBL] [Abstract][Full Text] [Related]
16. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cox ME; Deeble PD; Lakhani S; Parsons SJ Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001 [TBL] [Abstract][Full Text] [Related]
17. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells]. Song Y; Wu G; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464 [TBL] [Abstract][Full Text] [Related]
18. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430 [TBL] [Abstract][Full Text] [Related]
19. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359 [TBL] [Abstract][Full Text] [Related]